(CLPT) ClearPoint Neuro, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CLPT) ClearPoint Neuro, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This ClearPoint Neuro, Inc. 4P's Marketing Mix Analysis explains the company’s product offering, pricing, distribution, and promotion in a concise, structured view and shows how these decisions support market positioning. This page contains a real preview/sample of the analysis so you can review style and content before buying; purchase the full version for the complete ready-to-use report.
Product
ClearPoint system
ClearPoint system is ClearPoint Neuro, Inc.'s main platform for minimally invasive brain procedures, pairing real-time MRI guidance with operating-room navigation. It helps surgeons target deep brain structures with higher precision in functional neurosurgery. The system supports accurate placement for therapies that depend on millimeter-level control.
Deep brain stimulation placement
ClearPoint Neuro, Inc.'s Deep brain stimulation placement is built for MRI-guided, submillimeter-accurate electrode placement, which is the main value driver in DBS. DBS is a key therapy for movement and neurological disorders, including Parkinson's disease, which affects more than 10 million people worldwide. Better placement accuracy helps target the right brain area and can cut revision risk.
Biopsy needle guidance
ClearPoint Neuro, Inc. uses its guidance workflow to place biopsy needles into the brain with higher targeting precision, which matters in delicate cranial procedures. This product supports diagnostic neurosurgery by helping teams reach small lesions more accurately and with less manual guesswork. It fits the company’s image as a precision neuro-navigation provider for brain procedures.
Drug and laser catheter delivery
ClearPoint Neuro’s drug and laser catheter delivery tools let surgeons place medication infusions directly into the brain and guide laser catheters for local treatment, so the platform goes well beyond simple navigation. That matters in 4P terms because it adds higher-value procedure support, tighter targeting, and broader use in neurosurgery workflows.
- Direct brain drug delivery
- Laser catheter placement support
- Localized treatment workflow fit
- Expands beyond navigation
ClearPoint Neuro Navigation System
ClearPoint Neuro Navigation System is built for MRI suite use, so it fits imaging-led surgical workflows better than standard navigation tools. ClearPoint Neuro's edge is clear: it helps surgeons operate inside the constraints of live MRI guidance, where space, compatibility, and real-time visualization matter most. That makes it a niche, high-precision platform rather than a general OR system.
- MRI-suite engineered
- Fits imaging-based workflows
- Sets ClearPoint Neuro apart
- Built for precision guidance
ClearPoint Neuro: MRI-Guided Brain Surgery with Millimeter Accuracy
ClearPoint Neuro, Inc.’s Product centers on MRI-guided brain navigation for DBS, biopsy, and drug or laser catheter delivery, where millimeter accuracy matters. Its niche is live MRI compatibility, which helps surgeons place tools with less guesswork. In DBS, tighter targeting can lower revision risk; Parkinson’s affects over 10 million people worldwide.
| Product area | Core value |
|---|---|
| ClearPoint system | Real-time MRI guidance |
| DBS placement | Submillimeter targeting |
| Biopsy and delivery | Precision cranial access |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of ClearPoint Neuro’s product, pricing, placement, and promotion strategy.
Editable Excel File
Condenses ClearPoint Neuro’s 4Ps into a quick, structured snapshot that makes strategic review and communication easy.
Reference Sources
Provides a concise, traceable bibliography of primary industry reports, clinical data, and regulatory filings to speed due diligence and validate key assumptions.
Place
Solana Beach, California
Solana Beach, California is ClearPoint Neuro’s headquarters and anchor for its product, people, and strategy decisions. Founded in 1998 and rebranded from MRI Interventions, Inc. in February 2020, the Company reported 2025 revenue of about $31 million, showing the city’s role as its operating base.
United States focus
ClearPoint Neuro generates most of its business in the United States, where its sales and support are centered on medical institutions and neurosurgical centers. In fiscal 2025, the U.S. still represented the company’s core commercial base, with more than 90% of revenue tied to domestic activity.
Hospital MRI suites
ClearPoint Neuro, Inc.’s products are built for use inside MRI suite environments, so the Place strategy is tightly focused on specialized hospitals and surgical centers with 1.5T or 3T imaging systems. That makes access dependent on advanced imaging infrastructure, trained staff, and OR-MRI integration. In plain terms: no MRI suite, no sale.
Direct institutional sales
ClearPoint Neuro sells directly to hospitals, academic centers, and surgeons, which fits a procedure-heavy niche where training and support matter more than broad retail reach. This B2B model helps the Company keep tight control of adoption, while its 2025 revenue base of about $33 million shows the scale remains specialized, not mass-market.
- Direct sales to clinical buyers
- Best for complex neurosurgery workflows
- Supports training and service control
Partner-enabled reach
ClearPoint Neuro, Inc. expands reach through partner-led channels, especially licensing and collaboration deals that plug its platforms into larger medtech and research networks. That matters for a company with a 2025 market cap still far smaller than top-tier device peers, because each partner can add installed-base access without building a full direct sales force.
- Partners widen commercial access.
- Licensing lowers channel dependence.
- Research ties support faster adoption.
ClearPoint Neuro’s U.S.-Centric Reach Drives $31M Revenue
ClearPoint Neuro’s Place is highly concentrated in the United States, with direct sales to hospitals, academic centers, and neurosurgical sites that have MRI suite access. In fiscal 2025, revenue was about $31 million, and more than 90% came from domestic activity. Its reach also expands through partner and licensing channels, which extend access without a broad retail network.
| Place factor | 2025 data |
|---|---|
| HQ | Solana Beach, California |
| Revenue | About $31 million |
| U.S. share | More than 90% |
Preview the Actual Deliverable
ClearPoint Neuro, Inc. Reference Sources
The preview shown here is the actual ClearPoint Neuro, Inc. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.
Promotion
Neurosurgeon sales force
ClearPoint Neuro, Inc. uses a direct neurosurgeon sales force to reach a highly clinical buyer set, with promotion centered on face-to-face engagement with neurosurgeons and hospital teams. Technical demos and workflow talks matter most, because purchase decisions hinge on procedure fit, safety, and operating-room use. This sales model suits a niche market where one hospital win can influence several clinicians and service lines.
Clinical partnerships
ClearPoint Neuro uses clinical partnerships to build trust, with named links to The Johns Hopkins University and UCSF. These 2 flagship institutions give the technology visible third-party validation in high-acuity neurosurgery and research settings. That matters because peer-led adoption usually drives faster awareness than paid promotion alone.
Medical device alliances
ClearPoint Neuro uses 4 named alliances with Boston Scientific, Philips, Blackrock Neurotech, and Clinical Laserthermia Systems to widen visibility across neuromodulation and imaging. These partnerships help place ClearPoint Neuro inside a broader ecosystem of 4 markets: guidance, imaging, implants, and therapy delivery. Co-development and licensing are key promo themes that signal reach beyond its own platform.
Evidence-led messaging
ClearPoint Neuro, Inc. promotes with evidence-led messaging that centers on procedural accuracy, MRI guidance, and minimally invasive use. That fits capital medical tech, where clinical outcomes and technical differentiation drive adoption, not broad consumer-style branding. The message works best when it ties device precision to safer workflows and repeatable results.
- Focus on MRI-guided accuracy
- Stress minimally invasive delivery
- Use clinical outcome proof
- Highlight technical differentiation
Conference and professional outreach
ClearPoint Neuro, Inc. uses conference and professional outreach to reach a small, highly technical buyer set, so trust comes from data, not broad ads. Medical congresses, surgeon education, and peer-to-peer calls fit this market because neurosurgeons and hospital teams want proof on workflow, accuracy, and clinical use. This makes scientific communication the core promotion tool, especially in a niche where one strong KOL can influence adoption.
- Targets a narrow surgeon audience
- Uses congresses and education
- Relies on peer proof, not mass ads
Surgeon-Led Trust Powers ClearPoint Neuro’s Precision Growth
ClearPoint Neuro, Inc. promotes through a surgeon-led sales model, so proof comes from clinical demos, workflow talks, and peer trust. Its message centers on MRI-guided precision, minimally invasive use, and procedural safety, which fits a niche hospital buyer. Partnerships with Johns Hopkins, UCSF, Boston Scientific, Philips, Blackrock Neurotech, and CLS extend reach and credibility.
| Promotion lever | Key proof |
|---|---|
| KOL trust | 2 flagship institutions |
| Partner reach | 4 named alliances |
Price
No public list price
ClearPoint Neuro does not publish consumer-style list prices, so the "Price" is set through hospital and research center contracts. Sales are mainly institutional, which makes pricing case-by-case rather than retail. That means buyers usually negotiate based on order size, system mix, and service terms.
Quote-based contracts
ClearPoint Neuro, Inc. uses quote-based contracts, so hospitals and medical centers get custom pricing instead of a fixed list price. Final cost usually changes with configuration, order volume, and service terms, which is standard for specialized neurosurgical systems. This model fits a market where hospital purchasing cycles can run 12+ weeks and contract terms often drive total deal value.
Capital plus recurring revenue
ClearPoint Neuro’s price mix fits a capital-plus-recurring model: hospitals buy the system once, then keep paying for disposable or consumable items each case. That setup is common in surgical technology and can lift lifetime value because the installed base keeps generating procedure revenue after the upfront sale. ClearPoint Neuro reported about $32 million in 2024 revenue, showing how repeat use can matter as much as the first system sale.
Value-based pricing
ClearPoint Neuro uses value-based pricing, so the price reflects clinical precision, MRI integration, and procedural utility, not just hardware. Buyers judge the total workflow value, which supports a premium specialized-medtech position. In this model, hospitals pay for better targeting and easier MRI-guided use when that can improve procedure quality and efficiency.
- Price follows clinical value.
- MRI integration supports premium pricing.
- Total workflow matters more than device cost.
Institutional purchasing
Institutional purchasing at ClearPoint Neuro, Inc. is driven by hospitals, not patients, so pricing must fit budget cycles, reimbursement, and procedure volume. That matters in a market where U.S. hospital care made up 31.4% of national health spending in 2023, so price acceptance depends on clinical use and payer support.
- Buyer: hospital, not consumer
- Price tied to reimbursement
- Procedure volume shapes acceptance
ClearPoint Neuro’s Quote-Based Pricing Powers Recurring Revenue
ClearPoint Neuro’s Price is quote-based and set in institutional contracts, not retail list pricing. Hospitals pay for the system, then for recurring disposables, so total deal value depends on configuration, volume, and service terms. ClearPoint Neuro reported about $32 million in 2024 revenue, which shows how repeat procedure use supports pricing power.
| Price driver | What it means |
|---|---|
| Buyer | Hospitals and research centers |
| Pricing model | Custom contract pricing |
| Revenue type | Capital plus recurring disposables |
| Latest revenue | About $32 million in 2024 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.